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CC BY-NC-ND license (http://creativeRhinovirus has been neglected in the past because it was generally perceived as a respiratory
virus only capable of causing mild common cold. Contemporary epidemiological studies using
molecular assays have shown that rhinovirus is frequently detected in adult and pediatric pa-
tients with upper or lower respiratory tract infections. Severe pulmonary and extrapulmonary
complications are increasingly recognized. Contrary to popular belief, some rhinoviruses can
actually replicate well at 37 C and infect the lower airway in humans. The increasing availabil-
ity of multiplex PCR panels allows rapid detection of rhinovirus and provides the opportunity
for timely treatment and early recognition of outbreaks. Recent advances in the understanding
of host factors for viral attachment and replication, and the host immunological response in
both asthmatic and non-asthmatic individuals, have provided important insights into rhinovirus
infection which are crucial in the development of antiviral treatment. The identification of
novel drugs has been accelerated by repurposing clinically-approved drugs. As humoral anti-
bodies induced by past exposure and vaccine antigen of a particular serotype cannot provide
full coverage for all rhinovirus serotypes, novel vaccination strategies are required for inducing
protective response against all rhinoviruses.
Copyright ª 2017, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
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Rhinovirus e From bench to bedside 497without co-pathogens.2 Although most clinicians are aware
of rhinovirus, only few have access to diagnostic tests
which can provide rapid virological confirmation. The
increasing availability and affordability of commercially-
available molecular diagnostic tests has allowed rapid
diagnosis of rhinovirus infection in every day clinical prac-
tice. Recent advance in basic science research has
improved our understanding on the virology, pathogenesis
and immunological response of rhinovirus infection, which
aids the development of antiviral treatment and vaccines.
This review describes the advances in the understanding of
rhinovirus from basic and clinical research studies that are
relevant to clinical practice.
Virology
Taxonomy
Rhinovirus belongs to the Picornaviridae family. Before the
molecular era, rhinovirus is differentiated from enterovirus
phenotypically using acid stability test and serotyping with
specific antisera. Rhinovirus is inactivated by acid, while
enterovirus is acid stable. Different rhinoviruses can be
classified into major and minor group depending on cellular
receptor specificity, and into rhinovirus A and rhinovirus B
by differential susceptibility to capsid-binding compounds.3
The availability of molecular assay has further clarified the
genetic relatedness between rhinovirus and enterovirus,Fig. 1 Phylogenetic trees of VP4/VP2 (A) and 50UTR (B) of rhin
Enterovirus. Sequences for 1007 nucleotide positions in each VP4
included in the analysis. The trees were constructed by neighbor-joi
The scale bars indicate the estimated number of substitutions pe
parentheses) are presented as cited in the GenBank database. Ast
sequences.and between different rhinovirus species. For example,
rhinovirus 87 and enterovirus D68 are closely related
genetically, and both are acid sensitive. Rhinovirus 87 is
now reclassified as enterovirus D68.4
According to the latest ICTV release (http://ictvonline.
org/virusTaxonomy.asp. 2015 release), there are 3
rhinovirus species (Rhinovirus A, Rhinovirus B, Rhinovirus
C) under the genus Enterovirus, which also includes
Enterovirus AeH and Enterovirus J. Current taxonomy and
classification of rhinovirus and enterovirus are based on
capsid region, particularly VP4/VP2 and VP1 (Fig. 1A).5
Sequencing of the 50 untranslated region (50UTR) can
differentiate rhinovirus from enterovirus, but cannot un-
equivocally determine genetic type of rhinovirus strains
because 50UTR is one of the hotspots of recombination.6 In
particular, 50UTR cannot discriminate between rhinovirus A
and C (Fig. 1B).Viral genome and proteins
Rhinovirus is a non-enveloped, spherical virus with a
diameter of about 30 nm. The icosahedral capsid encloses a
7.2-kb positive-sense single-stranded RNA viral genome.7
The viral capsid is composed of the 4 capsid proteins.
VP1, VP2, VP3 are present on the cell surface, while VP4 is
found beneath the capsid. There are also several non-
structural proteins, which include 2A, 2B, 2C, 3A, 3B, 3C
and 3D. 2A and 3C are proteases, which cleaves viralovirus and enterovirus strains of 12 species within the genus
/VP2 and 718 nucleotide positions in each 50UTR region were
ning method, with bootstrap values calculated from 1000 trees.
r 20 bases in VP4/VP2 and 50UTR. The accession numbers (in
erisks indicate rhinovirus C variants with species A-like 50UTR
498 K.K.W. To et al.polyprotein.8 In addition to proteolytic cleavage of viral
polyproteins, 3C is also important for antagonizing antiviral
immunity. Rhinovirus 3C has been shown to cleave the host
complement C3 which prevents complement signaling,9 and
may also cleave the pathogen recognition receptor (PRR)
retinoic acid inducible gene I (RIG-I).10 3D is an RNA-
dependent RNA polymerase. Protein 2C, 2B and 3A are
important for anchoring replication complexes to mem-
branous structure of the host cell. Protein 2B is important
for the release of virus particles from cells by increasing the
cell membrane permeability and calcium efflux from the
endoplasmic reticulum. The viral capsid and proteases are
currently the major targets of antivirals. The viral capsid is
also the target site of neutralizing antibodies.
From 50 end, the viral genome consists of a 50VPg, a
50UTR, a long open reading frame encoding a polyprotein, a
30UTR and then a 30 poly-A tail.7 The viral genome is first
translated into a single polyprotein. This polyprotein is then
cleaved into P1, P2 and P3. P1 is further cleaved into VP0,
VP3 and VP1; P2 is further cleaved into 2A and 2BC, and P3
is further cleaved into 3AB and 3CD. VP0 is then cleaved
into VP4 and VP2; 2BC is cleaved into 2B and 2C; 3AB is
cleaved into 3A and 3B; and 3CD is cleaved into 3C and 3D.
Virus replication
Rhinovirus first attaches to cell surface by the binding be-
tween viral VP1 and the host cell surface receptor.
Depending on species, the host receptors can be intracel-
lular adhesion molecule 1 (ICAM-1), low-density lipoprotein
receptor (LDLR), heparan sulfate or cadherin-related family
member 3 (CDHR3).11 After attachment, viral entry
occurred via receptor-mediated endocytosis by clarithrin-
dependent or independent endocytosis, or via macro-
pinocytosis. Uncoating then occurs in low pH endosomes.
Inside the cytosol, viral RNA is translated into a poly-
protein. This polyprotein is cleaved by viral proteases into
smaller proteins. Viral RNA is also replicated to produce
negative-sense RNA and then positive-sense RNA in the
cytoplasm. Replication of rhinovirus requires the building
up of a replication complex, which involves lipids, proteins
and viral RNA. The new viral proteins and RNA are then
packaged. Viral export occurs via cell lysis.
Lipids play an important role in the viral replication.
Phosphatidylinositol 4-kinase III b (PI4KIIIb) is required for
rhinovirus infection.12 Inhibitors of PI4KIIIb has been shown to
inhibit rhinovirus C replication using a replicon construct
consisting of rhinovirus C genome sequences.13 However, un-
like enteroviruses, the recruitment of PI4KIIIb is independent
of GBF1 and ACBD3.14 Upon release, rhinovirus is enclosed in
phosphatidylserine vesicles, which enables them to be trans-
ferred to another cell for a new round of infection.15
Rhinovirus A and B can replicate in immortalized cell
lines, and rhinovirus C can replicate in ex vivo organ culture
of nasal epithelial cells.16 Rhinovirus C generated by
reverse genetics have also been shown to replicate in fully
differentiated human airway epithelial cells.17
Traditionally, it was thought that rhinovirus mainly causes
upper respiratory tract infection because it grows better at
33 C than at 37 C. However, studies have shown that some
rhinovirus strains grew equally well at both 33 C and 37 C.18Pathogenesis
Rhinovirus is primarily a respiratory tract pathogen.
Experimental infection in human volunteers showed that
rhinovirus can be detected throughout the respiratory
tract. In the upper respiratory tract, rhinovirus can be
detected in the nasal mucosa and posterior nasopharynx,
and mainly affects the ciliated epithelial cells and to a
lesser extent, non-ciliated cells.19 In the lower airway,
rhinovirus antigens can be detected in bronchial biopsy of
patients with experimental rhinovirus infection using in situ
hybridization.20,21 Rhinovirus is detected mainly in
columnar epithelial cells, and to a lesser extent, the basal
cell layer.20 Rhinovirus has also been shown to replicate in
type II pneumocytes derived from human fetal lung.22
Similar to other respiratory viruses,23,24 systemic dissemi-
nation of rhinovirus can occur. Rhinovirus viremia has been
associated with more severe disease.25 Live rhinovirus was
detected in blood and feces.26,27 Rhinovirus C RNA was
detected in fecal samples of patients with gastroenteritis,28
and in the cerebrospinal fluid of a fatal case of lower res-
piratory tract infection.27 Rhinovirus can also enter immune
cells, including monocytes, T cells and B cells. Rhinovirus
can replicate in B cells.29
Unlike influenza virus and adenovirus, rhinovirus does
not cause cytopathology in human nasal epithelial cell
line.30 However, rhinovirus can cause cytopathic changes in
human bronchial epithelial cells.20 Rhinovirus can also
cause disruption in the epithelial barrier, leading to
vascular leakage and mucus secretion.31 The disruption in
epithelial barrier has also been shown to facilitate the
binding, translocation and persistence of bacteria.31
Rhinovirus is a common co-pathogen in patients with
respiratory tract infection. In patients with chronic
obstructive pulmonary disease (COPD), there is significant
increase in bacterial load, especially Haemophilus influ-
enzae.32 Rhinovirus may also predispose to secondary bac-
terial infection by increasing the levels of neutrophil
elastase and decreasing the levels of antimicrobial
peptides.33
Experimental rhinovirus infection studies in patients
with asthma and COPD have significantly contributed to the
understanding of the pathogenesis regarding rhinovirus-
induced exacerbation of these chronic lung diseases.
Rhinovirus infection can trigger an inflammatory response
in the lower airway. In patients with asthma, rhinovirus
infection induces an increase in the levels of eosinophils in
bronchoalveolar lavage,34 and an increase in the levels of
IL-4, IL-5, IL-13, IL-25 and IL-33 in the nasal fluid.34,35 In
mice, antibody against IL-25 receptor abolished the
expression of TH2-related cytokines during rhinovirus
infection.35 IL-17A, which inhibits rhinovirus replication in
A549 cells, has been shown to reduce the expression in
peripheral blood mononuclear cells of asthmatic children
with rhinovirus infection.36 Experimental rhinovirus infec-
tion in COPD patients led to an increase in the level of IL-6
in the BAL, while no such increase occurs in non-COPD
patients.37
In addition to exacerbation of asthma and COPD,
rhinovirus has been implicated in the development of
asthma. It has been postulated that recurrent rhinovirus
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patients with asthma. Airway remodeling is characterized
by changes in reticular basement membrane, smooth
muscle mass, angiogenesis and barrier function. There is
also goblet cell hyperplasia and metaplasia which can lead
to increased mucus production.38Immune response
Innate immune response
Rhinovirus can be recognized by host cell via PRRs,
including toll-like receptors (TLRs), RIG-I-like receptors
(RLRs) and nucleotide-binding oligomerization domain
(NOD)-like receptors (NLRs).39 The activation of these PRRs
will trigger downstream signals, which are important for
limiting viral replication in immune regulation. For
example, TLR7 deficient-mice were found to have
increased in viral replication and exaggerated eosinophilic
inflammation.40 The binding of NLRs can activate caspase 1,
which regulates the processing and release of IL-18.
Blunted IL-18 response in the respiratory tract was associ-
ated with more symptoms in study participants with
experimental infection.41 Antimicrobial peptides may also
be important. LL-37 has been shown to inhibit rhinovirus
replication.42
Compared with RSV and influenza virus infection,
rhinovirus shows a distinctive RNA expression profile in the
peripheral blood. SOCS1 was uniquely found for rhino-
virus.43 SOCS1 is a member of the STAT-induced STAT in-
hibitor, which are negative regulators of cytokine signaling.
SOCS proteins negatively regulate the JAK-STAT pathway,
and Pim1 kinase can stabilize SOCS proteins. Inhibition of
Pim1 kinase, which increases the degradation of SOCS
proteins and augments the JAK-STAT pathway, has been
shown to reduce viral replication.44
The study of immune response of viral infections can
also be inferred by host genetic polymorphisms.45 In a study
with experimental rhinovirus infection, participants with a
polymorphism in the interleukin 6 (IL-6) promoter at posi-
tion 174 had more severe symptoms.46 In preterm infants
and term infants, genetic variants in vitamin D receptor and
IL-10 were associated with the development of lower res-
piratory tract infection.47,48Adaptive immunity
Rhinovirus infection can induce neutralizing antibody
response for the same serotype, but not across different
serotypes. Since there are >100 serotypes, frequent
rhinovirus infections due to different serotypes occur. In
human volunteers with experimental rhinovirus infection,
serotype-specific antibodies were generated after rhino-
virus infection, and that the IgG1 antibodies against the N-
terminal of VP1 fragment correlated with the severity of
upper and lower respiratory tract symptoms.49 The VP1 of
rhinovirus C has deletions where neutralizing antibody
binds for other rhinoviruses.50 However, it remains to be
determined whether VP1 protein of rhinovirus C can be the
binding site of neutralizing antibodies.T cells also play a role in rhinovirus infection. Human
intranasal challenge showed that there is rapid expansion
of epitope specific memory T cells after rhinovirus infec-
tion.51 T cell epitopes have been found on VP1 and VP2
capsid proteins.51,52 The exact role of T cell immunity in
limiting rhinovirus infection is not clear, but it has been
suggested that T cell recruitment may facilitate viral
clearance.7 For asthma patients, TH2 cells likely contribute
to asthmatic exacerbation by secreting IL-5 and IL-13.
Epidemiology
Rhinovirus is circulating worldwide. Most infected patients
are asymptomatic or only suffer from mild symptoms.53
Rhinovirus is one of the most common respiratory viruses
detected among patients with otitis media,54 croup,55
bronchiolitis,56 pneumonia57,58 and exacerbation of under-
lying lung diseases. Patients with severe rhinovirus in-
fections are more likely to be immunocompromised than
patients with influenza virus infection.59 Patients with
asthma also had more severe symptoms than healthy pa-
tients.60 Mortality rate can be high among critically ill pa-
tients. In an outbreak among infants in Vietnam, 12
critically ill infants with acute respiratory distress syn-
drome were admitted to the intensive care unit, and 7
patients died.61 Several studies have found that wheezing
episodes or lower respiratory tract infections were more
common among patients with rhinovirus C than rhinovirus A
or rhinovirus B.50,62,63 However, other studies did not find
any relationship between rhinovirus species and clinical
severity.64e66
In areas with temperate climates, the peak incidence of
rhinovirus infection occurs in early fall and in the spring. In
the subtropical areas such as Hong Kong, the seasonality is
similar.62,67 However, the severity of illness may depend on
the season. In a study conducted in Wisconsin USA, rhino-
virus is more likely to cause severe disease in the winter
months.68 In our recent study conducted in Hong Kong,
rhinovirus infection in critically ill patients occurred most
commonly during the summer and winter months, with
relatively few cases in the fall and spring.2 One possibility
of more severe rhinovirus infection during the winter may
be because at lower temperature, the induction of type I
and III interferons are much lower than that at higher
temperature.69
Most of the rhinovirus infections are acquired in the
community. However, several nosocomial or institutional
outbreaks have been reported, which affected both pa-
tients/residents or staff members.70,71 Being a non-
enveloped virus, rhinovirus is relatively resistant to
alcohol hand rub and disinfectants.72 Rhinovirus can be
detected on environmental surfaces for a prolonged period
of time.73
Clinical features
Rhinovirus most commonly causes “common cold”, an ill-
defined term which usually describes a clinical syndrome
with rhinorrhea, nasal congestion, sore throat, cough,
headache, and malaise, and can be caused by many respi-
ratory viruses and atypical bacteria. Other upper
500 K.K.W. To et al.respiratory tract infections include acute otitis media,74
rhinosinusitis75 and croup.76
Lower respiratory tract involvement is increasingly
recognized. Rhinovirus is commonly detected in patientswith
bronchiolitis and community acquired pneumonia
(CAP).57,58,76 Rhinovirus can also predispose to secondary
bacterial pneumonia. Since asymptomatic shedding is com-
mon, the pathogenic role of rhinovirus in lower respiratory
tract infection has been questioned. In caseecontrol studies,
rhinovirus was detected less frequently among children with
CAP than those who are apparently healthy.77,78 In a pro-
spective study comparing CAP patients and asymptomatic
controls, rhinovirus was associated with CAP only in adults,
but not in children.53 However, several lines of evidence
suggest that rhinovirus can cause lower respiratory tract
infection. Firstly, experimental infections in human volun-
teers showed that rhinovirus can infect the bronchial tis-
sue.20,21 Secondly, rhinovirus can replicate in cells originated
from the lower respiratory tract,22 and able to replicate at
37 C. Thirdly, experimental infection in human volunteers
with asthma or COPD showed that rhinovirus infection can
induce lower respiratory tract symptoms and decrease peak
expiratory flow and forced expiratory volume.34,37 Fourthly,
the viral load is significantly higher in patients with symptoms
than those who are asymptomatic.74,79
Rhinovirus has been associated with the exacerbation of
chronic lung diseases, including asthma,80 COPD,81 bron-
chiectasis,82 bronchiolitis obliterans organizing pneumonia2
and cystic fibrosis.83 Rhinovirus infection triggers more se-
vere symptoms and greater reduction in airway obstruction
in patients with asthma than non-asthmatic controls.34,84
Experimental rhinovirus infection in humans also induced
COPD exacerbation.37
Extrapulmonary complications are frequently seen in
critically ill patients with rhinovirus infection. In our study
on critically ill patients, seizure was identified in 23% of
patients with rhinovirus infection.2 Other extrapulmonary
complications include pulmonary edema, diabetic ketoaci-
dosis and hyperosmolar coma.
Diagnosis
Currently, reverse transcription-polymerase chain reaction
(RT-PCR) is the most common method in the detection of
rhinovirus from clinical specimens because it is much more
sensitive than viral culture. Amajor problem in themolecular
diagnosis of rhinovirus is the difficulty in differentiating
rhinovirus from enterovirus. The 50UTR is the most popular
target for the detection of rhinovirus because of high sensi-
tivity. However, RT-PCR targeting 50UTR without sequencing
cannot reliably differentiate between rhinovirus and
enterovirus, because it is difficult to find primer target sites
that are substantially different between rhinovirus and
enterovirus but identical among all rhinovirus species. There
is also some concern regarding the sensitivity in the detection
of rhinovirus C. The sensitivity of detection seems to be lower
for rhinovirus C than that for other rhinovirus species,85which
may be related to the highly variable target region.
Current commercially available multiplex PCR assays can
detect rhinovirus. Since most multiplex PCR assays cannot
reliably differentiate rhinovirus and enterovirus, the resultis reported as rhinovirus/enterovirus.86 Some commercially
available multiplex diagnostic platforms report rhinovirus
separately from enterovirus. Anyplex II RV16 has shown
good differentiation between rhinovirus and enterovirus for
a limited number of rhinovirus and enterovirus species
tested, but this assay has lower sensitivity than xTAG res-
piratory pathogen panel.87 Cross reactivity has been found
for enterovirus 68 in the GenMark Diagnostics eSensor res-
piratory viral panel.88
Since prolonged viral shedding can occur, the detection
of rhinovirus may be related to a past infection rather than
the current infection. However, in children <1 year old, it
was found that prolonged viral shedding beyond 30 days is
uncommon (<5%).89
Treatment
There is currently no approved treatment for rhinovirus
infections. Pleconaril, a capsid-binding drug which prevents
the interaction between virus and host cell receptor, was
the first antiviral against rhinovirus which has undergone
clinical trial. In two parallel randomized, double-blind,
placebo-controlled trials, the duration of symptoms was
significantly shorter than the placebo group if the drug is
taken within the first 24 h of symptoms.90 However, the
United States Food and Drug Administration advisory com-
mittee rejected the manufacturer’s application. The safety
concerns included menstrual disorders in women taking
pleconaril and oral contraceptives, and two women became
pregnant while taking pleconaril and oral contraceptives.91
Several capsid-binding drugs have been developed
recently.7 WIN56921 can inhibit both rhinovirus-A16 and
rhinovirus-C15, but not rhinovirus-B14.16
Other potential antiviral targets are the protease pro-
teins. Ruprintrivir is an inhibitor of the rhinovirus 3C pro-
tease. In double-blind placebo-controlled clinical trials,
intranasal ruprintrivir spray was effective in both the pre-
vention and treatment of experimental rhinovirus infection
in humans.92 However, in subsequent natural infection
studies, there was no significant reduction in viral load or
disease severity.93
Repurposing of approved drug is a popular strategy to
identify new drugs against respiratory virus infection. Using
a chemical screening library, the antifungal drug itracona-
zole has been found to have antiviral activities against
various viruses in the Picornaviridae family, including
rhinovirus.94 The antiviral action on rhinovirus was based on
the inhibition of oxysterol-binding protein (OSBP). OSBP is
involved in the shuttling of cholesterol and PIP4 between ER
and Golgi, which is important for rhinovirus replication.95 In
a murine model, oral administration of itraconazole
reduced the replication of rhinovirus in the lung of infected
mice.96 Nasal itraconazole prior to infection showed good
protection in mice as well.96 Another clinically-approved
drug with antiviral activity against rhinovirus is niclosa-
mide, an anti-helminth drug. Niclosamide inhibits viral
entry by neutralizing the acidic endosome.97
Phase 3 trials have been completed for echinacea,
vitamin C, zinc and anti-histamines. There is improvement
in symptoms for vitamin C, zinc and anti-histamines.7
However, there was no significant reduction in viral load.
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should contain antibodies against different serotypes of
rhinoviruses. Intravenous immunoglobulin has been used in
patients with severe rhinovirus infection.98
Vaccine
Studies conducted over 50 years ago showed that immuni-
zation with live attenuated or inactivated rhinovirus can
protect humans from challenge with homologous virus, but
not from heterologous virus from different serotypes.99 In
recent years, there are two mains strategies to induce
protective immunity against different rhinovirus serotypes.
A polyvalent inactivated rhinovirus vaccine, which contains
50 rhinovirus serotypes, has been tested in rhesus ma-
caques, and was shown to induce potent neutralizing
antibody against a broad range of subtypes.100 Another
approach is to use a conserved region of the rhinovirus as
the vaccine antigen, together with an adjuvant which en-
hances T cell response. In a mouse model, immunization
with recombinant rhinovirus 16 VP0 protein and incomplete
freund’s and CpG adjuvant elicited neutralizing antibodies
against both homologous and heterologous serotypes and
an increase in lung memory T cells.101 Mice immunized with
this adjuvanted VP0 vaccine showed more rapid viral
clearance when compared with non-immunized mice.
Conclusion
Besides being the most common cause of absence from work
or school, rhinovirus is increasingly recognized as a cause of
severe respiratory tract infection, which may be followed by
pulmonary and extrapulmonary complications in patients
with predisposing factors. The increasing availability of mo-
lecular test, which allows the early detection of rhinovirus,
has now provided the window of opportunity for treatment
studies during acute infection. Furthermore, early detection
will allow prompt recognition of outbreaks, which frequently
occur in hospitals and long term care facilities. Better un-
derstanding of the virus will allow the development of anti-
virals and therapeutic neutralizing antibody besides
symptomatic treatment. An effective vaccine, which either
contains multiple rhinovirus serotypes or a conserved region,
will be needed to overcome the difficulty in inducing immu-
nity against heterologous serotypes. It remains to be deter-
mined whether an effective vaccine can reduce pneumonia,
development or exacerbation of chronic pulmonary diseases,
and extrapulmonary complications.
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